Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1

Bone Marrow Transplantation volume 56, pages 1603–1613 (2021)Cite this article

Subjects

Abstract

We attempted to identify the incidence and survival outcome of hepatic sinusoidal obstruction syndrome/veno-occlusive disease (VOD/SOS) after hematopoietic cell transplantation (HCT) under strategy of prophylactic ursodiol and intravenous heparin or prostaglandin E1 (PGE1). From 2009 to 2018, 2572 consecutive allogeneic-HCT cases were reviewed. We used oral ursodiol for all transplants, and most were administered low-dose heparin, while PGE1 in selected cases with low platelet count at the time of preconditioning. Diagnosis and severity grades were reassessed by revised EBMT criteria. The overall incidence of hepatic VOD/SOS was 3.4% (Mild 0.9%, Moderate 0.6%, Severe 0.7%, Very severe 1.2%) after allogeneic-HCT under strategy of intravenous prophylaxis. The 1-year overall survival of VOD/SOS was 41.4% which was divided into 73.9% for mild, 66.7% for moderate, 38.9% for severe, and 6.5% for very severe grade. Very high disease risk index, male gender, donor other than matched sibling donor, and busulfex > 9 mg/kg were affecting factors for development of VOD/SOS. For severe to very severe VOD/SOS, history of pre-HCT liver dysfunction was an additionally affecting factor. Allogeneic-HCT using ursodiol and intravenous prophylaxis was considered safe without significant bleeding complications and should be evaluated in future clinical trials. For those with high-risk of VOD/SOS, early intervention and management is important.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Analyzed patients for identification of post-HCT hepatic VOD/SOS incidence.
Fig. 2: Survival outcomes according to VOD/SOS and the severity grades.
Fig. 3: Survival outcomes according to major treatment strategy of VOD/SOS.

Similar content being viewed by others

References

  1. Yoon JH, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Bone Marrow Transpl. 2019;54:1361–8. https://doi.org/10.1038/s41409-019-0492-6

    Article  Google Scholar 

  2. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024

    Article  Google Scholar 

  3. Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transpl. 2010;45:1287–93. https://doi.org/10.1038/bmt.2009.349

    Article  CAS  Google Scholar 

  4. Yoon JH, Min WS, Kim HJ, Kim JH, Shin SH, Yahng SA, et al. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Bone Marrow Transpl. 2013;48:1562–8. https://doi.org/10.1038/bmt.2013.101

    Article  CAS  Google Scholar 

  5. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.

    Article  CAS  Google Scholar 

  6. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451–62.

    Article  Google Scholar 

  7. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599–604.

    CAS  PubMed  Google Scholar 

  8. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301–9. https://doi.org/10.1016/S0140-6736(11)61938-7

    Article  CAS  PubMed  Google Scholar 

  9. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2018;53:138–45. https://doi.org/10.1038/bmt.2017.161

    Article  CAS  Google Scholar 

  10. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396–404. e-pub ahead of print 2005/10/13

    PubMed  Google Scholar 

  11. Tsirigotis PD, Resnick IB, Avni B, Grisariu S, Stepensky P, Or R, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transpl. 2014;49:1389–92. https://doi.org/10.1038/bmt.2014.168

    Article  CAS  Google Scholar 

  12. Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl. 2011;17:1713–20. https://doi.org/10.1016/j.bbmt.2011.06.006

    Article  Google Scholar 

  13. Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, et al. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transpl. 2006;38:823–4. https://doi.org/10.1038/sj.bmt.1705528

    Article  CAS  Google Scholar 

  14. Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304–13. https://doi.org/10.1200/JCO.1993.11.2.304

    Article  CAS  PubMed  Google Scholar 

  15. Marks DI, Kebriaei P, Stelljes M, Gokbuget N, Kantarjian H, Advani AS, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2019;25:1720–9. https://doi.org/10.1016/j.bbmt.2019.04.020

    Article  CAS  Google Scholar 

  16. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl J Med. 2016;375:740–53. https://doi.org/10.1056/NEJMoa1509277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transpl. 2001;27:627–33. https://doi.org/10.1038/sj.bmt.1702854

    Article  CAS  Google Scholar 

  18. Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transpl. 2006;37:677–86. https://doi.org/10.1038/sj.bmt.1705297

    Article  CAS  Google Scholar 

  19. Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol. 1990;74:277–81. https://doi.org/10.1111/j.1365-2141.1990.tb02583.x

    Article  CAS  PubMed  Google Scholar 

  20. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834–40.

    Article  CAS  Google Scholar 

  21. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:206–17. https://doi.org/10.1016/j.bbmt.2006.09.012

    Article  CAS  Google Scholar 

  22. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71. https://doi.org/10.1182/blood-2014-01-552984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873–83. https://doi.org/10.1002/cncr.31874

    Article  CAS  PubMed  Google Scholar 

  24. Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol. 2010;92:342–50. https://doi.org/10.1007/s12185-010-0649-y

    Article  CAS  PubMed  Google Scholar 

  25. Lee SE, Kim YJ, Yahng SA, Cho BS, Eom KS, Lee S, et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol. 2011;87:510–20. https://doi.org/10.1111/j.1600-0609.2011.01697.x

    Article  CAS  PubMed  Google Scholar 

  26. Shin SH, Jeon YW, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transpl. 2016;51:1456–63. https://doi.org/10.1038/bmt.2016.171

    Article  CAS  Google Scholar 

  27. Lee SE, Park SS, Jeon YW, Yoon JH, Cho BS, Eom KS, et al. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: prospective de-escalation study of TBI and ATG dose. Am J Hematol. 2018;93:1368–75. https://doi.org/10.1002/ajh.25257

    Article  CAS  PubMed  Google Scholar 

  28. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–22.

    Article  CAS  Google Scholar 

  29. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83. e-pub ahead of print 1987/12/01

    Article  CAS  Google Scholar 

  30. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2015;50:781–9. https://doi.org/10.1038/bmt.2015.52

    Article  CAS  Google Scholar 

  31. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906–12. https://doi.org/10.1038/bmt.2016.130

    Article  CAS  Google Scholar 

  32. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656–65. https://doi.org/10.1182/blood-2015-10-676924

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2:1495–509. https://doi.org/10.1182/bloodadvances.2017008375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Richardson PG, Triplett BM, Ho VT, Chao N, Dignan FL, Maglio M, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Exp Rev Clin Pharmacol. 2018;11:113–24. https://doi.org/10.1080/17512433.2018.1421943

    Article  CAS  Google Scholar 

  35. Kim DS. Introduction: health of the health care system in Korea. Soc Work Public Health. 2010;25:127–41. https://doi.org/10.1080/19371910903070333

    Article  CAS  PubMed  Google Scholar 

  36. Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403–9. https://doi.org/10.1038/bmt.2015.283

    Article  CAS  Google Scholar 

  37. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(12 Pt 1):975–81. https://doi.org/10.7326/0003-4819-128-12_part_1-199806150-00002

    Article  CAS  PubMed  Google Scholar 

  38. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977–83. https://doi.org/10.1182/blood-2001-12-0159

    Article  CAS  PubMed  Google Scholar 

  39. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32–38. https://doi.org/10.1002/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n

    Article  CAS  Google Scholar 

  40. Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2002;29:137–43. https://doi.org/10.1038/sj.bmt.1703342

    Article  CAS  Google Scholar 

  41. Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol. 1991;47:346–54. https://doi.org/10.1111/j.1600-0609.1991.tb01859.x

    Article  CAS  PubMed  Google Scholar 

  42. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996;61:1067–71. https://doi.org/10.1097/00007890-199604150-00014

    Article  CAS  PubMed  Google Scholar 

  43. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol. 1993;84:724–30. https://doi.org/10.1111/j.1365-2141.1993.tb03152.x

    Article  CAS  PubMed  Google Scholar 

  44. Song JS, Seo JJ, Moon HN, Ghim T, Im HJ. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci. 2006;21:897–903. https://doi.org/10.3346/jkms.2006.21.5.897

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112–8. https://doi.org/10.1111/bjh.14727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome: interim results from a treatment IND study. Biol Blood Marrow Transpl. 2017;23:997–1004. https://doi.org/10.1016/j.bbmt.2017.03.008

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim & Seok Lee

Authors
  1. Jae-Ho Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gi June Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung-Soo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung-Eun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Byung-Sik Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ki-Seong Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoo-Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chang-Ki Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Seok-Goo Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dong-Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jong Wook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hee-Je Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hee-Je Kim or Seok Lee.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Consent for publication

Written informed consent was obtained at the stage of transplantation in all patients.

Ethics approval and consent to participate

This research was conducted in accordance with the Institutional Review Board guidelines of the Catholic Medical Center (KC20RISI0132/199).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoon, JH., Min, G.J., Park, SS. et al. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. Bone Marrow Transplant 56, 1603–1613 (2021). https://doi.org/10.1038/s41409-021-01215-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01215-y

This article is cited by

Search

Advanced search

Quick links